MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy-Reference-Cited by-同舟云学术

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy

Published:2023-07 Issue:7 Volume:18 Page:907-921
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

He Kai,Berz David,Gadgeel Shirish M.,Iams Wade T.,Bruno Debora S.,Blakely Collin M.,Spira Alexander I.,Patel Manish R.,Waterhouse David M.,Richards Donald A.,Pham Anthony,Jotte Robert,Hong David S.,Garon Edward B.,Traynor Anne,Olson Peter,Latven Lisa,Yan Xiaohong,Shazer Ronald,Leal Ticiana A.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference44 articles.

1. Nivolumab versus docetaxel in Advanced nonsquamous non–small-cell lung cancer;Borghaei;N Engl J Med,2015

2. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer;Brahmer;N Engl J Med,2015

3. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer;Reck;N Engl J Med,2016

4. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189;Rodríguez-Abreu;Ann Oncol,2021

5. Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis;Shen;Eur J Hosp Pharm,2023

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

2. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer;Cancer Immunology, Immunotherapy;2024-09-05

3. Rechallenge de l’immunothérapie par nivolumab pour un cancer épidermoïde du larynx en poursuite évolutive après échec des modalités conventionnelles de traitement : cas clinique CARE;Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale;2024-09

4. Investigation of cell mechanics and migration on DDR2-expressing neuroblastoma cell line;2024-08-16

5. Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report;European Annals of Otorhinolaryngology, Head and Neck Diseases;2024-08